Scilex Holding Presents Poster On ELYXYB At The Annual Scientific Meeting Of The AHS To Be Held On June 13-16, 2024
Scilex Holding Presents Poster On ELYXYB At The Annual Scientific Meeting Of The AHS To Be Held On June 13-16, 2024
Scilex控股公司將在2024年6月13日至16日舉行的AHS年度科學會議上展示有關ELYXYB的海報。
- Up to 60% of patients with migraine do not sufficiently respond to triptans.
- Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post-hoc analysis of two Phase 3 randomized clinical trials.
- In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB-treated arm achieved 2-hour pain freedom (the gold standard for efficacy endpoint in migraine) than placebo (33.3% vs. 14.3%, p=0.0036). The likelihood of achieving pain freedom was 200% greater with ELYXYB than with placebo (OR=3.0).
- 高達60%的偏頭痛患者對三聯療法的反應不足。
- Celecoxib口服溶液對於偏頭痛的急性治療，針對三聯療法反應不足的參與者：兩個3期隨機臨床試驗後的事後分析結果的彙總。
- 對於對三聯療法反應不足的患者，ELYXYB治療組達到2小時無痛自由（偏頭痛療效終點的黃金標準）的患者明顯比安慰劑組更多（33.3％與14.3％，p = 0.0036）。使用ELYXYB獲得無痛自由的可能性比使用安慰劑增加了200％（OR = 3.0）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。